<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liver flukes: Fascioliasis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liver flukes: Fascioliasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Liver flukes: Fascioliasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fascioliasis is a trematode flatworm infection caused by <em>Fasciola hepatica</em> or <em>Fasciola gigantica</em> [<a href="#rid1">1</a>]. <em>F. hepatica</em> has a worldwide distribution; <em>F. gigantica</em> occurs predominantly in the tropics. Both parasites are hermaphroditic, have similar life cycles, and cause similar clinical manifestations in humans. The organism causes "liver rot" among sheep and cattle, which are the definitive hosts; humans are incidental hosts.</p><p class="headingAnchor" id="H2"><span class="h1">FASCIOLA HEPATICA</span></p><p class="headingAnchor" id="H3"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span><em>F. hepatica</em> occurs globally, mainly in sheep-rearing areas of temperate climates. Infection is endemic in Central and South America (especially Bolivia and Peru), Europe (especially Portugal, France, Spain, and Turkey), Asia (especially China, Vietnam, Taiwan, Korea, and Thailand), Africa, and the Middle East [<a href="#rid2">2</a>]. It is estimated that 50 percent of the world's infection burden of fascioliasis occurs in the Andean Plateau [<a href="#rid3">3,4</a>]. Sporadic cases have also been reported in the United States [<a href="#rid5">5</a>], Australia [<a href="#rid6">6</a>], and elsewhere [<a href="#rid1">1</a>]. An estimated 2.4 to 17 million people are infected in more than 51 countries [<a href="#rid7">7</a>]; 180 million are at risk worldwide [<a href="#rid8">8</a>]. Children are commonly infected. </p><p>Sheep and cattle are the most important definitive hosts of <em>F. hepatica</em>; goats, buffalo, horses, donkeys, camels, hogs, deer, and rabbits can also be infected. By infecting livestock, fascioliasis causes significant problems to industry and farmers. Snails are intermediate hosts. Humans are incidental hosts and most often acquire infection by eating watercress or water chestnuts grown in sheep-raising areas. Infection may also be transmitted by other freshwater plants, including water lettuce, mint, alfalfa, and parsley. Humans can also acquire infection by drinking contaminated water containing viable metacercariae [<a href="#rid9">9</a>]; outbreaks have been described [<a href="#rid10">10</a>]. The incidence of animal and human infection rises during wet years because of an increased number of snails and longer survival of encysted cercariae [<a href="#rid11">11</a>].</p><p>In some areas, endemicity is almost 100 percent. In endemic regions, very young children and women are most likely to be infected. There is a high incidence of coinfection with other parasites, especially echinococcosis. The geographic distribution of infection and transmission risks are expanding due to human and livestock migration, climate change, and man-made modifications of the environment [<a href="#rid12">12,13</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Life cycle</span><span class="headingEndMark"> — </span>The life cycle of fascioliasis begins with release of unembryonated eggs into the biliary ducts, which are then passed in the stool of herbivores (definitive hosts) or humans (incidental hosts) (<a class="graphic graphic_figure graphicRef50779" href="/z/d/graphic/50779.html" rel="external">figure 1</a>). Eggs become embryonated in water and release miracidia, which invade a snail (intermediate host), where the parasites undergo several developmental stages (sporocysts, rediae, and cercariae). The cercariae are released and encyst as metacercariae on aquatic vegetation.</p><p>Sheep, cattle, or humans acquire infection by eating vegetation containing metacercariae. After ingestion, the metacercariae excyst in the duodenum and migrate through the intestinal wall, peritoneal cavity, and liver parenchyma into the biliary ducts, where they develop into adults; in humans, this takes three to four months. The adult flukes reside in the large biliary ducts of the mammalian host.</p><p>Migrating metacercariae cause liver parenchymal destruction, since tracks undergo necrosis and fibrosis. In addition, adult flukes can partially obstruct the bile ducts, causing thickening, dilatation, and fibrosis of the proximal biliary tree [<a href="#rid14">14</a>]. The amount of liver damage is correlated with the parasite load; the number of adult flukes that reach the biliary tree and develop to sexual maturity is usually small. The life span of adult <em>F. hepatica</em> flukes within humans is estimated to be 9 to 13 years.</p><p class="headingAnchor" id="H6"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Many infections are mild; morbidity increases with fluke burden [<a href="#rid15">15</a>]. Forms of infection include the acute (liver) phase, chronic (biliary) phase, ectopic fascioliasis, and pharyngeal fascioliasis.</p><p class="headingAnchor" id="H7"><span class="h3">Acute (liver) phase</span><span class="headingEndMark"> — </span>Acute symptoms usually begin within 6 to 12 weeks of metacercariae ingestion. The early phase of migration through the liver is often associated with fever, right upper quadrant pain, and hepatomegaly. Jaundice is occasionally observed (<a class="graphic graphic_table graphicRef55607" href="/z/d/graphic/55607.html" rel="external">table 1</a>). Other symptoms include anorexia, nausea, vomiting, weight loss, myalgia, cough, and urticaria. Marked peripheral eosinophilia is almost always present. The acute phase can be complicated by hemobilia or subcapsular hematomas of the liver [<a href="#rid9">9</a>]. In most cases, acute symptoms generally resolve after about six weeks, although, in very heavy infections, extensive liver parenchymal necrosis can result.</p><p>Extrahepatic symptoms may also occur during the acute phase, likely related to an immunologic or allergic mechanism [<a href="#rid11">11</a>]. A Loeffler-like syndrome or right-sided pleural effusion containing many eosinophils may be observed [<a href="#rid2">2,16</a>]. The urticaria may be associated with pruritus and dermatographia [<a href="#rid17">17</a>]. Pericarditis, cardiac conduction abnormalities, meningeal symptoms, focal neurologic changes, or seizures have also been described but are uncommon. </p><p class="headingAnchor" id="H8"><span class="h3">Chronic (biliary) phase</span><span class="headingEndMark"> — </span>The chronic phase usually begins about six months after infection and may last 10 years or more [<a href="#rid18">18</a>]. This phase is usually asymptomatic, although epigastric and right upper quadrant pain, diarrhea, nausea, vomiting, wasting, hepatomegaly, and jaundice can occur. Common bile duct obstruction can develop, and chronic infection can lead to biliary colic, cholangitis, cholelithiasis, and obstructive jaundice. Secondary pancreatitis has been reported in up to 30 percent of cases [<a href="#rid19">19,20</a>]. Parasite eggs or adult worms may serve as a nidus for stone formation, leading to intra- or extrahepatic biliary lithiasis. Prolonged and/or heavy infection can also result in sclerosing cholangitis and biliary cirrhosis. Peripheral eosinophilia may or may not be present in the biliary phase.</p><p class="headingAnchor" id="H9"><span class="h3">Ectopic fascioliasis</span><span class="headingEndMark"> — </span>Extrahepatic involvement may occur; it is unknown whether the parasites migrate to ectopic sites hematogenously or through soft tissues. Ectopic fascioliasis results in eosinophilic and mononuclear infiltration with secondary tissue damage. The most common ectopic site is the subcutaneous tissue of the abdominal wall. The lungs, heart, brain, muscle, genitourinary tract, skin, and the eye may also be affected [<a href="#rid21">21-23</a>]. Tender, migrating, erythematous, itchy nodules (1 to 6 cm in diameter) can develop; in some cases, these may result in localized abscesses. Generalized lymphadenopathy may also develop [<a href="#rid14">14</a>]. Cerebral manifestations include space occupying lesions, cerebral infarction, and hemorrhage (intracerebral, subdural, or subarachnoid) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Pharyngeal fascioliasis</span><span class="headingEndMark"> — </span>Pharyngeal fascioliasis is a form of fascioliasis that occurs in the Middle East; it is acquired by consumption of raw liver of an infected animal [<a href="#rid25">25</a>]. The living fluke can attach to the upper respiratory or digestive tract, causing an allergic pharyngitis with edema and congestion; suffocation may result.</p><p>This condition is also known as ‘Halzoun syndrome.’ The syndrome was first described in Lebanon in 1905 and initially attributed to <em>Fasciola hepatica</em>; subsequent publications have also attributed it to other pathogens including <em>Dicrocoelium dendriticum</em> and <em>Linguatula serrata </em>[<a href="#rid26">26</a>]<em>.</em> </p><p class="headingAnchor" id="H11"><span class="h2">Diagnosis</span></p><p class="headingAnchor" id="H1840423687"><span class="h3">Clinical approach</span><span class="headingEndMark"> — </span>The diagnosis of fascioliasis should be considered in patients with abdominal pain and hepatomegaly accompanied by peripheral eosinophilia. A careful dietary history should be obtained, including a history of watercress ingestion or consumption of raw vegetables washed in potentially contaminated water [<a href="#rid27">27</a>].</p><p>The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens. Alternative approaches to diagnosis include identification of adult worms in endoscopic or surgical specimens or serology. Imaging can be an adjunctive diagnostic tool. Additional diagnostic clues include anemia, abnormal liver function tests, elevated erythrocyte sedimentation rate, and hypergammaglobulinemia.</p><p>Diagnosis of fascioliasis should prompt evaluation of family members. (See <a class="local">'Follow-up'</a> below.)</p><p>There is often a delay in diagnosis of fascioliasis. In one review of patients with fascioliasis in developed countries, symptoms related to acute infection preceded the diagnosis for ≥1 month in 73 percent of cases [<a href="#rid20">20</a>]. In another review with patients with biliary-phase fascioliasis, the delay was even longer (symptoms for 1 to 208 weeks; mean 64 weeks).</p><p class="headingAnchor" id="H12"><span class="h3">Microscopy</span><span class="headingEndMark"> — </span>The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens. However, eggs are not detectable in stool during the acute phase of infection or in the setting of ectopic fascioliasis. (See <a class="local">'Acute (liver) phase'</a> above and <a class="local">'Ectopic fascioliasis'</a> above.)</p><p>Eggs of <em>F. hepatica </em>are oval, yellow-brown, and measure 130 to 150 micrometers long by 60 to 90 micrometers wide (<a class="graphic graphic_picture graphicRef70390" href="/z/d/graphic/70390.html" rel="external">picture 1</a>). It can be difficult to distinguish between the eggs of <em>F. hepatica</em>, <em>F. gigantica</em>, and the intestinal fluke <em>Fasciolopsis buski</em>. Specimen concentration facilitates egg identification. Examination of multiple specimens may be needed because egg excretion may be intermittent; negative stool examinations do not exclude the diagnosis.</p><p>Since stool examination may be negative during the acute phase or in the setting of ectopic fascioliasis, in such cases, the diagnosis may require serology or examination of surgical specimens following removal of the parasite [<a href="#rid28">28</a>].</p><p>Liver biopsy rarely demonstrates eggs or adult flukes [<a href="#rid29">29</a>]. Histopathologic changes that may suggest fascioliasis include Charcot-Leyden crystals, eosinophils, and multiple calcific foci [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H4733004"><span class="h3">Endoscopy or surgery</span><span class="headingEndMark"> — </span>The diagnosis may be made during surgery or endoscopy for biliary obstruction when adult flukes are found in the biliary tree. On endoscopic retrograde cholangiopancreatography (ERCP), adult flukes may appear as small, radiolucent linear, elliptical, or crescent-like shadows, with jagged, irregular margins in the gallbladder or dilated bile ducts [<a href="#rid31">31,32</a>]. Laparoscopy may also demonstrate nodules in the liver capsule. </p><p>The adult <em>F. hepatica</em> flukes are large, flat, brown, and leaf shaped, measuring approximately 30 mm in length by 15 mm wide (<a class="graphic graphic_picture graphicRef65725" href="/z/d/graphic/65725.html" rel="external">picture 2</a>). The broad anterior portion is covered with scale-like spines.</p><p class="headingAnchor" id="H13"><span class="h3">Serology</span><span class="headingEndMark"> — </span>Serology usually becomes positive during the early phase of migration through the liver; therefore, it is useful for diagnosing early symptoms prior to the appearance of eggs in the stool. It is also useful in ectopic disease, when eggs are not detectable in the stool.</p><p>Serologic tests include indirect hemagglutination, complement fixation, counterimmunoelectrophoresis, immunofluorescence assays, and enzyme-linked immunosorbent assay (ELISA). In general, these tests have good sensitivity, but many have suboptimal specificity and cross-react with other parasitic infections.</p><p>ELISA-based assays, especially ones that use genus-specific antigens, have largely replaced other techniques because they are sensitive, rapid, and quantitative [<a href="#rid33">33-35</a>]. A variety of different antigens, such as Fas2, CL1, SAP2, and FhSAP2, have been used. For example, in a study among 634 Peruvian children with fascioliasis, the Fas2-ELISA (cathepsin L1-based antibody) had high sensitivity and specificity (92 and 84 percent, respectively) [<a href="#rid36">36</a>]. In another study, an ELISA employing a recombinant form of the <em>F. hepatica</em> cathepsin L1 as the antigen showed 99.9 percent sensitivity and 99.9 percent specificity [<a href="#rid37">37</a>].</p><p>Many antigens have been evaluated in in-house assays; the United States Centers for Disease Control and Prevention (CDC) recommends enzyme immunoassays (EIA) with excretory-secretory (ES) antigens combined with confirmation of positive results by immunoblot [<a href="#rid38">38</a>]. The CDC immunoblot assay is based on a recombinant F. hepatica antigen (FhSAP2) and has a reported sensitivity and specificity of 94 and 98 percent, respectively [<a href="#rid39">39</a>]. Specific antibodies to <em>Fasciola</em> may be detectable two to four weeks following infection (which is five to seven weeks before eggs appear in stool). Successful treatment often correlates with a decline in ELISA titers, although antibodies may be detectable for years after infection [<a href="#rid40">40</a>].</p><p>An ELISA antigen capture technique that detects circulating antigens is available and has a reported sensitivity and specificity of 100 and 98 percent, respectively [<a href="#rid41">41</a>]. Antigen levels correlate with burden of infection [<a href="#rid42">42</a>]. In addition, the assay is diagnostic prior to the appearance of eggs in the stool so is particularly useful for diagnosis during acute infection. The assay becomes negative in approximately 65 percent of patients one month after successful therapy [<a href="#rid43">43,44</a>]. Tests that detect antigens in stool have also been developed but are not commercially available [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H4264558"><span class="h3">Molecular testing</span><span class="headingEndMark"> — </span>Real-time polymerase chain reaction (PCR) on stool is emerging as an alternative diagnostic technique with high sensitivity, but is not yet commercially available [<a href="#rid46">46-48</a>]. PCR on the aspirate from a liver abscess has also been used for diagnosis [<a href="#rid49">49</a>]. Molecular testing of environmental water samples has also been described [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Imaging</span><span class="headingEndMark"> — </span>Useful radiographic tools for fascioliasis include computed tomography (CT), ultrasonography, cholangiography, ERCP, and magnetic resonance imaging (MRI) (<a class="graphic graphic_diagnosticimage graphicRef86430" href="/z/d/graphic/86430.html" rel="external">image 1</a>) [<a href="#rid51">51</a>]. A review of radiographic findings in fascioliasis noted that multiple small (up to 25 mm in diameter) nodular and branching lesions were the most common findings; these frequently occur in the subcapsular area of the liver parenchyma. They most often appear hypoechoic on ultrasonography, hypodense on CT, and T2 hyper- and T1 hypointense on MRI [<a href="#rid52">52</a>]. Peripheral enhancement on postcontrast images is characteristic [<a href="#rid53">53</a>]. Necrotic areas may be seen especially in larger lesions [<a href="#rid54">54</a>].</p><p>CT scanning of the liver may demonstrate characteristic hypodense nodules or tortuous tracks due to migration of the parasite through the liver [<a href="#rid2">2</a>]. Thickening of the liver capsule, subcapsular hematoma, or parenchymal calcifications may also be detected [<a href="#rid55">55</a>].</p><p>Ultrasonography, cholangiography, and ERCP are useful in the biliary stage of infection. These techniques may demonstrate mobile leaf-like flukes in the bile ducts and gallbladder, often associated with stones [<a href="#rid56">56</a>]. Irregular thickening of the common bile duct wall may be observed [<a href="#rid57">57</a>]. Peri-portal lymphadenopathy and hepatomegaly and/or splenomegaly may be seen, especially in acute fascioliasis [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H2181118"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of fascioliasis varies according to the stage of infection.</p><p>In the acute phase (fever, right upper quadrant pain, and eosinophilia as well as extrahepatic symptoms including a Loeffler-like syndrome), the differential diagnosis includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Toxocariasis – Toxocariasis (also called visceral larva migrans) refers to human infection caused by roundworms that are not natural human parasites; larvae migrate through the liver and lungs, resulting in hepatitis and/or pneumonitis. The diagnosis can be confirmed by ELISA antibody assay. (See  <a class="medical medical_review" href="/z/d/html/5716.html" rel="external">"Toxocariasis: Visceral and ocular larva migrans"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute schistosomiasis – Schistosomiasis is caused by infection with parasitic blood flukes; clinical manifestations of acute infection include sudden onset of fever, urticaria and angioedema, chills, myalgias, arthralgias, dry cough, diarrhea, abdominal pain, and headache. Among returned travelers, the diagnosis is established via serology; in endemic areas, microscopy can be used to determine the infecting species and the burden of infection, although it is less helpful in the setting of early infection. (See  <a class="medical medical_review" href="/z/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/z/d/html/5682.html" rel="external">"Schistosomiasis: Diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ascariasis – Ascariasis is a roundworm infection; clinical manifestations in sensitized individuals include transient respiratory symptoms during larval migration through the lungs; the pneumonitis is known as Loeffler syndrome. The diagnosis of ascariasis is usually established via stool microscopy. (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Strongyloidiasis – Strongyloidiasis is a roundworm infection associated with transpulmonary migration of larvae, which can produce dry cough, throat irritation, dyspnea, wheezing, and hemoptysis. A Loeffler-like syndrome with eosinophilia is rarely observed. The diagnosis is usually made by detecting rhabditiform larvae in concentrated stool or via serologic methods. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.)</p><p></p><p>In the setting of multiple liver lesions, the differential diagnosis includes the following conditions. <em>F. hepatica</em> infection may be able to be distinguished from these alternative conditions based on its radiographic appearance (multiple branching lesions).</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy (primary or secondary) – Patients with hepatocellular carcinoma may have manifestations of cirrhosis and/or hepatic decompensation; patients with metastatic tumors may have findings related to the underlying malignancy (eg, rectal bleeding in a patient with colon cancer). The evaluation includes radiography and laboratory testing. (See  <a class="medical medical_review" href="/z/d/html/3575.html" rel="external">"Approach to the adult patient with an incidental solid liver lesion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyogenic abscess – Clinical manifestations of pyogenic liver abscess include fever and abdominal pain. Other common symptoms include nausea, vomiting, anorexia, weight loss, and malaise. The diagnosis is confirmed radiographically followed by aspiration and culture of abscess material. (See  <a class="medical medical_review" href="/z/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amebic liver abscess – Clinical manifestations of amebic liver abscess include right upper quadrant pain and fever. The diagnosis is generally established by radiographic imaging and confirmed with serologic or antigenic testing, perhaps supplemented with stool microscopy or antigenic testing of stool, with or without evaluation for the parasite in liver abscess fluid. (See  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis", section on 'Amebic liver abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echinococcosis – Echinococcosis may cause a liver lesion; radiographic findings include membranes, mixed echogenicity, hydatid sand, and/or daughter cysts with characteristic internal septation. This appearance differs from the hypoechoic branching lesions seen with fascioliasis. (See  <a class="medical medical_review" href="/z/d/html/5669.html" rel="external">"Echinococcosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p>In the biliary phase, the differential diagnoses includes other infectious and noninfectious causes of biliary obstruction:</p><p class="bulletIndent1"><span class="glyph">●</span>Biliary ascariasis, opisthorchiasis, and clonorchiasis – The specific diagnosis can be established via microscopy or endoscopic retrograde cholangiopancreatography. (See related topics.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholelithiasis, cholangitis, cholecystitis, and cholangiocarcinoma – Patients may present with right upper quadrant pain with elevated liver enzymes in a primarily cholestatic pattern, but with fascioliasis liver lesions may also be seen as a mobile leaf-like fluke in the bile ducts. (See related topics).</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H4038056875"><span class="h3">Clinical approach</span><span class="headingEndMark"> — </span>Treatment of fascioliasis consists of anthelminthic therapy. Additional intervention may be needed depending on the nature of the clinical presentation. </p><p class="headingAnchor" id="H2462530611"><span class="h3">Anthelminthic therapy</span><span class="headingEndMark"> — </span>The treatment of choice is <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> [<a href="#rid58">58,59</a>]; bithionol and <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> are alternative choices [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H16"><span class="h4">Triclabendazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">Triclabendazole</a> is an imidazole derivative. It is effective against all stages of fascioliasis with a cure rate of &gt;90 percent [<a href="#rid18">18,60</a>]. Dosing consists of 10 mg/kg orally for one or two days. The drug is relatively well tolerated; absorption is improved by postprandial administration, preferably following a fatty meal. The US Food and Drug Administration has approved a recommendation of a total dose of 20 mg/kg (two 10 mg/kg doses given 12 hours apart) for treatment of patients aged 6 years or more [<a href="#rid38">38,59</a>]. Triclabendazole has been administered in children &lt;6 years of age despite limited safety and efficacy data [<a href="#rid61">61</a>].</p><p>A review of <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> reported efficacy data in observational studies [<a href="#rid62">62</a>]. Early efficacy reports came from open-label, uncontrolled studies using an efficacy endpoint of parasitologic cure, based on the absence of Fasciola spp eggs in stool samples at day 60. Overall cure rates (using triclabendazole 10 mg/kg as a single dose or split into two 5 mg/kg doses) ranged from 64 to 100 percent; however participant numbers in each individual study were small (30 or fewer). Subsequent cases series confirmed cure rates of 70 to 80 percent (with single-dose triclabendazole) in acute and chronic stages of fascioliasis, and cure rates of 75 to 100 percent (with total dose 20 mg/kg triclabendazole; 10 mg/kg doses given on consecutive days) [<a href="#rid63">63-68</a>]. Juvenile parasites migrating through the liver seem to have reduced susceptibility to triclabendazole compared with mature parasites [<a href="#rid69">69</a>].</p><p>In one study including 90 Bolivian children treated with a two-dose <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> regimen, cure rates were 78 percent after one treatment and 98 percent after two treatments; egg reduction rates ranged between 74 to 90 percent after one treatment and 84 to 99 percent after two treatments. The proportion of high-intensity infections (≥400 eggs) decreased from 8 to 1 percent after one treatment and to 0 percent after two treatments [<a href="#rid65">65</a>]. </p><p>Cases of <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> resistance in livestock have been described [<a href="#rid70">70,71</a>]. The mechanism of resistance of triclabendazole to <em>Fasciola</em> is unknown [<a href="#rid72">72</a>]. Human treatment failures have been reported and may be due to resistance [<a href="#rid61">61,73-76</a>], although some studies have shown cure following repeated triclabendazole doses [<a href="#rid77">77</a>].</p><p><a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">Triclabendazole</a> prolongs the QTc interval. The primary treatment complication consists of biliary obstruction by dead parasites, which may occur three to seven days following treatment and may require removal by ERCP [<a href="#rid78">78,79</a>]. </p><p class="headingAnchor" id="H17"><span class="h4">Alternative agents</span><span class="headingEndMark"> — </span>There are no well-established alternative agents to <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> for treatment of fascioliasis [<a href="#rid80">80</a>], although limited evidence for <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> based on observational data and one trial of 65 Peruvian patients with fascioliasis [<a href="#rid81">81,82</a>] suggests that this can be considered. Nitazoxanide was well tolerated, and cure was achieved in 40 percent of children and 60 percent of adults compared with 6 percent in the placebo group (p&lt;0.05). Dosing consisted of 500 mg twice daily for seven days. Bithionol has been used but is no longer available.</p><p>In general, <em>F. hepatica</em> responds poorly to <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a>. <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">Mebendazole</a> and <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> are not effective. <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">Artesunate</a> is also not effective [<a href="#rid66">66,83</a>]; in one randomized trial comparing <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> and artesunate, triclabendazole had greater efficacy in terms of resolution of symptoms (92 versus 76 percent), eosinophilia (42 versus 16 percent), and ultrasound findings (70 versus 66 percent) [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Additional interventions</span><span class="headingEndMark"> — </span>Biliary decompression (endoscopic, percutaneous, or surgical) may be warranted in some circumstances; indications may include biliary duct stones and/or cholangitis [<a href="#rid56">56,57</a>]. Worms may be extracted after creation of a small sphincterotomy (<a class="graphic graphic_diagnosticimage graphicRef116477" href="/z/d/graphic/116477.html" rel="external">image 2</a>). Bile should be sent to evaluate for eggs and adult worms. </p><p>Issues related to management of complications (such as biliary obstruction, stone formation, cholangitis, cholecystitis, liver abscess, pancreatitis, hepatitis, and cirrhosis) are discussed separately. (See related topics.)</p><p class="headingAnchor" id="H3132174"><span class="h3">Follow-up</span><span class="headingEndMark"> — </span>Follow-up after therapy should include monitoring for resolution of eosinophilia, clearance of eggs in stool, and a decrease in serology titers. It is reasonable to repeat all tests that were initially positive at three months. Resolution of biliary tract findings on ultrasound after therapy may also be helpful [<a href="#rid84">84</a>].</p><p>In one case series including 24 asymptomatic individuals with positive stool tests for eggs who were treated with <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a>, a negative follow-up stool examination was reported in 79 percent after a single dose; 12 months after therapy, serologic tests were negative in more than 90 percent of the patients who were cured [<a href="#rid34">34</a>].</p><p>Diagnosis of fascioliasis should prompt screening of family members with serology (stool microscopy is not generally helpful since eggs are often absent early in infection). In one study of 326 adults in Peru, adults with fascioliasis were four times more likely to live with an infected child [<a href="#rid85">85</a>]. Asymptomatic individuals should be treated to avoid the risk of future complications.</p><p class="headingAnchor" id="H20"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Infection can be prevented by avoiding ingestion of raw freshwater plants in endemic areas. Elimination of the snail intermediate hosts has also been attempted by molluscicide application and pasture drainage but, in general, is not practical.</p><p>Vaccine studies in animal models have shown reduction in worm burdens and egg production of approximately 70 percent; no vaccines are available for human use [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H21"><span class="h1">FASCIOLA GIGANTICA</span><span class="headingEndMark"> — </span><em>F. gigantica</em> is closely related to <em>F. hepatica</em>. It infects domestic livestock in warm tropical and subtropical areas in Africa, the Western Pacific, Hawaii, and Southeast Asia [<a href="#rid4">4</a>]. Herbivorous mammals are the definitive hosts and snails (genus <em>Lymnaea</em>) are the intermediate hosts; humans are incidental hosts.</p><p><em>F. gigantica</em> has a similar life cycle and pathology to <em>F. hepatica</em> and also causes similar clinical manifestations in the acute (liver) phase, in the chronic (biliary) phase, and in ectopic sites. The eggs (190 by 90 microns) and the adult flukes (up to 7.5 cm in length) are larger than <em>F. hepatica</em>.</p><p>Diagnosis of <em>F. gigantica</em> can be challenging. Eggs are often not detected in the stool and serodiagnosis is often inconclusive. Reports have suggested that specific antigens of <em>F. gigantica</em> can be detected by indirect enzyme-linked immunosorbent assay or immunoblot with good sensitivity and specificity [<a href="#rid87">87,88</a>]. Immunochromatographic tests for serodiagnosis have been developed using antigens from adult <em>F. gigantica</em> excretory-secretory product and recombinant <em>F. gigantica</em> cathepsin L, with the former showing superior sensitivity and specificity (100 and 99 percent, respectively) among a small number of patients [<a href="#rid89">89</a>]. A polymerase chain reaction-restriction fragment length polymorphism assay has been used to distinguish between <em>F. hepatica</em> and <em>F. gigantica</em> but is not widely available [<a href="#rid90">90</a>]. Until diagnostic techniques improve, recovery of adult flukes in the appropriate epidemiologic setting can be used to exclude or confirm the diagnosis.</p><p>Treatment and preventive measures are the same as for <em>F. hepatica</em>.</p><p class="headingAnchor" id="H3132407"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Fascioliasis is a trematode flatworm infection caused by <em>Fasciola hepatica</em> or <em>Fasciola gigantica</em>. <em>F. hepatica</em> has a worldwide distribution; <em>F. gigantica</em> occurs predominantly in the tropics. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Herbivorous mammals are the definitive hosts, snails are intermediate hosts, and humans are incidental hosts (<a class="graphic graphic_figure graphicRef50779" href="/z/d/graphic/50779.html" rel="external">figure 1</a>). Sheep, cattle, or humans acquire infection by eating aquatic vegetation containing metacercariae, which excyst in the duodenum and migrate through the intestinal wall, peritoneal cavity, and liver parenchyma into the biliary ducts, where they develop into adults. (See <a class="local">'Life cycle'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many infections are mild; morbidity increases with fluke burden. The acute (liver) phase of migration is often associated with fever, right upper quadrant pain, and hepatomegaly. Jaundice is occasionally observed. Other symptoms include anorexia, nausea, vomiting, myalgia, cough, and urticaria. Marked peripheral eosinophilia is frequently present. (See <a class="local">'Acute (liver) phase'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The chronic (biliary) phase usually begins about six months after infection and may last 10 years or more. This phase is usually asymptomatic, although epigastric and right upper quadrant pain, diarrhea, nausea, vomiting, wasting, hepatomegaly, and jaundice can occur. Common bile duct obstruction can develop, and chronic infection can lead to biliary colic, cholangitis, cholelithiasis, pancreatitis, and obstructive jaundice. (See <a class="local">'Chronic (biliary) phase'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens (<a class="graphic graphic_picture graphicRef70390" href="/z/d/graphic/70390.html" rel="external">picture 1</a>). Alternative approaches to diagnosis include identification of adult worms in endoscopic or surgical specimens or serology. Imaging can be a helpful adjunctive diagnostic tool. Additional diagnostic clues include eosinophilia, abnormal liver function tests, and anemia. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">triclabendazole</a> for treatment of fascioliasis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing is outlined above. Management of ascending cholangitis requires antibiotics and surgery. Biliary obstruction may require endoscopic retrograde cholangiopancreatography and direct removal of the parasites if possible. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mas-Coma S. Epidemiology of fascioliasis in human endemic areas. J Helminthol 2005; 79:207.</a></li><li class="breakAll">Mahanty S, Maclean JD, Cross JH. Liver, Lung, and Intestinal Fluke Infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.854.</li><li><a class="nounderline abstract_t">Tanabe MB, Prochaska J, Morales ML, et al. Geospatial analysis of the associations between environmental contamination with livestock feces and children with chronic fascioliasis in the Anta province of Cusco, Peru. PLoS Negl Trop Dis 2022; 16:e0010499.</a></li><li><a class="nounderline abstract_t">Angles R, Buchon P, Valero MA, et al. One Health Action against Human Fascioliasis in the Bolivian Altiplano: Food, Water, Housing, Behavioural Traditions, Social Aspects, and Livestock Management Linked to Disease Transmission and Infection Sources. Int J Environ Res Public Health 2022; 19.</a></li><li><a class="nounderline abstract_t">Weisenberg SA, Perlada DE. Domestically acquired fascioliasis in northern California. Am J Trop Med Hyg 2013; 89:588.</a></li><li><a class="nounderline abstract_t">Sivagnanam S, van der Poorten D, Douglas MW. Hepatic lesions and eosinophilia in an urban dweller. Liver Int 2014; 34:643.</a></li><li><a class="nounderline abstract_t">Mas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol 2009; 69:41.</a></li><li><a class="nounderline abstract_t">Pan M, Bai SY, Ji TK, et al. Epidemiology of Fasciola spp. in the intermediate host in China: A potential risk for fasciolosis transmission. Acta Trop 2022; 230:106394.</a></li><li><a class="nounderline abstract_t">Chan CW, Lam SK. Diseases caused by liver flukes and cholangiocarcinoma. Baillieres Clin Gastroenterol 1987; 1:297.</a></li><li><a class="nounderline abstract_t">Bjorland J, Bryan RT, Strauss W, et al. An outbreak of acute fascioliasis among Aymara Indians in the Bolivian Altiplano. Clin Infect Dis 1995; 21:1228.</a></li><li><a class="nounderline abstract_t">Arjona R, Riancho JA, Aguado JM, et al. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore) 1995; 74:13.</a></li><li><a class="nounderline abstract_t">Webb CM, Cabada MM. Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection. Curr Opin Infect Dis 2018; 31:409.</a></li><li><a class="nounderline abstract_t">Alba A, Vazquez AA, Hurtrez-Boussès S. Towards the comprehension of fasciolosis (re-)emergence: an integrative overview. Parasitology 2021; 148:385.</a></li><li><a class="nounderline abstract_t">Harinasuta T, Pungpak S, Keystone JS. Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis. Infect Dis Clin North Am 1993; 7:699.</a></li><li><a class="nounderline abstract_t">Adachi S, Kotani K, Shimizu T, et al. Asymptomatic fascioliasis. Intern Med 2005; 44:1013.</a></li><li><a class="nounderline abstract_t">Krsak M, Patel NU, Poeschla EM. Case Report: Hepatic Fascioliasis in a Young Afghani Woman with Severe Wheezing, High-Grade Peripheral Eosinophilia, and Liver Lesions: A Brief Literature Review. Am J Trop Med Hyg 2019; 100:588.</a></li><li><a class="nounderline abstract_t">Micic D, Oto A, Charlton MR, et al. Hiding in the Water. N Engl J Med 2020; 382:1844.</a></li><li><a class="nounderline abstract_t">Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008; 21:523.</a></li><li><a class="nounderline abstract_t">Sezgın O, Altintaş E, Tombak A, Uçbılek E. Fasciola hepatica-induced acute pancreatitis: report of two cases and review of the literature. Turk J Gastroenterol 2010; 21:183.</a></li><li><a class="nounderline abstract_t">Kaya M, Beştaş R, Cetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World J Gastroenterol 2011; 17:4899.</a></li><li><a class="nounderline abstract_t">Xuan le T, Hung NT, Waikagul J. Cutaneous fascioliasis: a case report in Vietnam. Am J Trop Med Hyg 2005; 72:508.</a></li><li><a class="nounderline abstract_t">Dalimi A, Jabarvand M. Fasciola hepatica in the human eye. Trans R Soc Trop Med Hyg 2005; 99:798.</a></li><li><a class="nounderline abstract_t">Taghipour A, Zaki L, Rostami A, et al. Highlights of human ectopic fascioliasis: a systematic review. Infect Dis (Lond) 2019; 51:785.</a></li><li><a class="nounderline abstract_t">Hughes G, Green CA, Street D, et al. Case Report: Subarachnoid Hemorrhage and Eosinophilic Meningitis due to Disseminated Fascioliasis. Am J Trop Med Hyg 2020; 102:574.</a></li><li><a class="nounderline abstract_t">Saleha AA. Liver fluke disease (fascioliasis): epidemiology, economic impact and public health significance. Southeast Asian J Trop Med Public Health 1991; 22 Suppl:361.</a></li><li><a class="nounderline abstract_t">Khalil G, Haddad C, Otrock ZK, et al. Halzoun, an allergic pharyngitis syndrome in Lebanon: the trematode Dicrocoelium dendriticum as an additional cause. Acta Trop 2013; 125:115.</a></li><li><a class="nounderline abstract_t">el-Shabrawi M, el-Karaksy H, Okasha S, el-Hennawy A. Human fascioliasis: clinical features and diagnostic difficulties in Egyptian children. J Trop Pediatr 1997; 43:162.</a></li><li><a class="nounderline abstract_t">Prociv P, Walker JC, Whitby M. Human ectopic fascioliasis in Australia: first case reports. Med J Aust 1992; 156:349.</a></li><li><a class="nounderline abstract_t">Price TA, Tuazon CU, Simon GL. Fascioliasis: case reports and review. Clin Infect Dis 1993; 17:426.</a></li><li><a class="nounderline abstract_t">Acosta-Ferreira W, Vercelli-Retta J, Falconi LM. Fasciola hepatica human infection. Histopathological study of sixteen cases. Virchows Arch A Pathol Anat Histol 1979; 383:319.</a></li><li><a class="nounderline abstract_t">Cheung J, Enns R, Romney M, et al. Biliary fascioliasis. Gastrointest Endosc 2005; 61:596.</a></li><li><a class="nounderline abstract_t">Bektaş M, Dökmeci A, Cinar K, et al. Endoscopic management of biliary parasitic diseases. Dig Dis Sci 2010; 55:1472.</a></li><li><a class="nounderline abstract_t">Mansour WA, Kaddah MA, Shaker ZA, et al. A monoclonal antibody diagnoses active Fasciola infection in humans. J Egypt Soc Parasitol 1998; 28:711.</a></li><li><a class="nounderline abstract_t">Apt W, Aguilera X, Vega F, et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52:532.</a></li><li><a class="nounderline abstract_t">Mirzadeh A, Jafarihaghighi F, Kazemirad E, et al. Recent Developments in Recombinant Proteins for Diagnosis of Human Fascioliasis. Acta Parasitol 2021; 66:13.</a></li><li><a class="nounderline abstract_t">Espinoza JR, Maco V, Marcos L, et al. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. Am J Trop Med Hyg 2007; 76:977.</a></li><li><a class="nounderline abstract_t">Gonzales Santana B, Dalton JP, Vasquez Camargo F, et al. The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease. PLoS Negl Trop Dis 2013; 7:e2414.</a></li><li class="breakAll">Centers for Disease Control and Prevention. DPDx: Fascioliasis. https://www.cdc.gov/dpdx/fascioliasis/index.html (Accessed on November 11, 2020).</li><li><a class="nounderline abstract_t">Shin SH, Hsu A, Chastain HM, et al. Development of Two FhSAP2 Recombinant-Based Assays for Immunodiagnosis of Human Chronic Fascioliasis. Am J Trop Med Hyg 2016; 95:852.</a></li><li><a class="nounderline abstract_t">Santiago N, Hillyer GV. Antibody profiles by EITB and ELISA of cattle and sheep infected with Fasciola hepatica. J Parasitol 1988; 74:810.</a></li><li><a class="nounderline abstract_t">Shaheen HI, Kamal KA, Farid Z, et al. Dot-enzyme-linked immunosorbent assay (dot-ELISA) for the rapid diagnosis of human fascioliasis. J Parasitol 1989; 75:549.</a></li><li><a class="nounderline abstract_t">Hassan MM, Saad M, Hegab MH, Metwally S. Evaluation of circulating Fasciola antigens in specific diagnosis of fascioliasis. J Egypt Soc Parasitol 2001; 31:271.</a></li><li><a class="nounderline abstract_t">Shehab AY, Hassan EM, Basha LM, et al. Detection of circulating E/S antigens in the sera of patients with fascioliasis by IELISA: a tool of serodiagnosis and assessment of cure. Trop Med Int Health 1999; 4:686.</a></li><li><a class="nounderline abstract_t">Hammouda NA, el Mansoury ST, el Azzouni MZ, Hussein ED. Detection of circulating antigens in blood to evaluate treatment of fascioliasis. J Egypt Soc Parasitol 1997; 27:365.</a></li><li><a class="nounderline abstract_t">Siles-Lucas M, Becerro-Recio D, Serrat J, González-Miguel J. Fascioliasis and fasciolopsiasis: Current knowledge and future trends. Res Vet Sci 2021; 134:27.</a></li><li><a class="nounderline abstract_t">Calvani NED, Windsor PA, Bush RD, Šlapeta J. Scrambled eggs: A highly sensitive molecular diagnostic workflow for Fasciola species specific detection from faecal samples. PLoS Negl Trop Dis 2017; 11:e0005931.</a></li><li><a class="nounderline abstract_t">Cabada MM, Malaga JL, Castellanos-Gonzalez A, et al. Recombinase Polymerase Amplification Compared to Real-Time Polymerase Chain Reaction Test for the Detection of Fasciola hepatica in Human Stool. Am J Trop Med Hyg 2017; 96:341.</a></li><li><a class="nounderline abstract_t">Carnevale S, Malandrini JB, Pantano ML, et al. Use of the PCR in a Combined Methodological Approach for the Study of Human Fascioliasis in an Endemic Area. Acta Parasitol 2021; 66:455.</a></li><li><a class="nounderline abstract_t">L'Ollivier C, Eldin C, Lambourg E, et al. Case Report: First Molecular Diagnosis of Liver Abscesses Due to Fasciola hepatica Acute Infection Imported from Vietnam. Am J Trop Med Hyg 2020; 102:106.</a></li><li><a class="nounderline abstract_t">Rathinasamy V, Hosking C, Tran L, et al. Development of a multiplex quantitative PCR assay for detection and quantification of DNA from Fasciola hepatica and the intermediate snail host, Austropeplea tomentosa, in water samples. Vet Parasitol 2018; 259:17.</a></li><li><a class="nounderline abstract_t">Cevikol C, Karaali K, Senol U, et al. Human fascioliasis: MR imaging findings of hepatic lesions. Eur Radiol 2003; 13:141.</a></li><li><a class="nounderline abstract_t">Koç Z, Ulusan S, Tokmak N. Hepatobiliary fascioliasis: imaging characteristics with a new finding. Diagn Interv Radiol 2009; 15:247.</a></li><li><a class="nounderline abstract_t">Salahshour F, Tajmalzai A. Imaging findings of human hepatic fascioliasis: a case report and review of the literature. J Med Case Rep 2021; 15:324.</a></li><li><a class="nounderline abstract_t">Teke M, Önder H, Çiçek M, et al. Sonographic findings of hepatobiliary fascioliasis accompanied by extrahepatic expansion and ectopic lesions. J Ultrasound Med 2014; 33:2105.</a></li><li><a class="nounderline abstract_t">Van Beers B, Pringot J, Geubel A, et al. Hepatobiliary fascioliasis: noninvasive imaging findings. Radiology 1990; 174:809.</a></li><li><a class="nounderline abstract_t">Sezgin O, Altintaş E, Dişibeyaz S, et al. Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management. J Clin Gastroenterol 2004; 38:285.</a></li><li><a class="nounderline abstract_t">Dias LM, Silva R, Viana HL, et al. Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP. Gastrointest Endosc 1996; 43:616.</a></li><li><a class="nounderline abstract_t">Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother 2004; 5:1711.</a></li><li class="breakAll">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a class="nounderline abstract_t">Marcos LA, Tagle M, Terashima A, et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008; 78:222.</a></li><li><a class="nounderline abstract_t">Morales ML, Tanabe MB, White AC Jr, et al. Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1. Emerg Infect Dis 2021; 27:1850.</a></li><li><a class="nounderline abstract_t">Gandhi P, Schmitt EK, Chen CW, et al. Triclabendazole in the treatment of human fascioliasis: a review. Trans R Soc Trop Med Hyg 2019; 113:797.</a></li><li><a class="nounderline abstract_t">el-Karaksy H, Hassanein B, Okasha S, et al. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J Trop Pediatr 1999; 45:135.</a></li><li><a class="nounderline abstract_t">Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33:1.</a></li><li><a class="nounderline abstract_t">Villegas F, Angles R, Barrientos R, et al. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS Negl Trop Dis 2012; 6:e1720.</a></li><li><a class="nounderline abstract_t">Keiser J, Sayed H, el-Ghanam M, et al. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS Negl Trop Dis 2011; 5:e1285.</a></li><li><a class="nounderline abstract_t">Millán JC, Mull R, Freise S, et al. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63:264.</a></li><li><a class="nounderline abstract_t">Talaie H, Emami H, Yadegarinia D, et al. Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. Clin Exp Pharmacol Physiol 2004; 31:777.</a></li><li><a class="nounderline abstract_t">Duthaler U, Smith TA, Keiser J. In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78. Antimicrob Agents Chemother 2010; 54:4596.</a></li><li><a class="nounderline abstract_t">Fairweather I. Triclabendazole progress report, 2005-2009: an advancement of learning? J Helminthol 2009; 83:139.</a></li><li><a class="nounderline abstract_t">Garcia HH, Moro PL, Schantz PM. Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. Curr Opin Infect Dis 2007; 20:489.</a></li><li><a class="nounderline abstract_t">Marcos L, Maco V, Terashima A. Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures. Expert Rev Anti Infect Ther 2021; 19:817.</a></li><li><a class="nounderline abstract_t">Winkelhagen AJ, Mank T, de Vries PJ, Soetekouw R. Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands. Emerg Infect Dis 2012; 18:1028.</a></li><li><a class="nounderline abstract_t">Kelley JM, Elliott TP, Beddoe T, et al. Current Threat of Triclabendazole Resistance in Fasciola hepatica. Trends Parasitol 2016; 32:458.</a></li><li><a class="nounderline abstract_t">Cabada MM, Lopez M, Cruz M, et al. Treatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case Series. PLoS Negl Trop Dis 2016; 10:e0004361.</a></li><li><a class="nounderline abstract_t">Branco EA, Ruas R, Nuak J, Sarmento A. Treatment failure after multiple courses of triclabendazole in a Portuguese patient with fascioliasis. BMJ Case Rep 2020; 13.</a></li><li><a class="nounderline abstract_t">Terashima A, Canales M, Maco V, Marcos LA. Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens. J Glob Antimicrob Resist 2021; 25:264.</a></li><li><a class="nounderline abstract_t">Luther RA, Wang D, Kim TK, et al. Crawling Into View. Clin Infect Dis 2019; 69:1079.</a></li><li><a class="nounderline abstract_t">Behzad C, Lahmi F, Iranshahi M, Mohammad Alizadeh AH. Finding of biliary fascioliasis by endoscopic ultrasonography in a patient with eosinophilic liver abscess. Case Rep Gastroenterol 2014; 8:310.</a></li><li><a class="nounderline abstract_t">Cabada MM, White AC Jr. New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis 2012; 25:518.</a></li><li><a class="nounderline abstract_t">Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 1998; 92:103.</a></li><li><a class="nounderline abstract_t">Favennec L, Jave Ortiz J, Gargala G, et al. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003; 17:265.</a></li><li><a class="nounderline abstract_t">Hien TT, Truong NT, Minh NH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008; 78:388.</a></li><li><a class="nounderline abstract_t">Richter J, Freise S, Mull R, Millán JC. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole. Trop Med Int Health 1999; 4:774.</a></li><li><a class="nounderline abstract_t">Caravedo MA, Ramirez W, Morales ML, et al. Fasciola hepatica Infection Risk for Adult Household Members Living with Children with Fascioliasis in Cusco, Peru. Am J Trop Med Hyg 2021; 104:2069.</a></li><li><a class="nounderline abstract_t">Spithill TW, Piedrafita D, Smooker PM. Immunological approaches for the control of fasciolosis. Int J Parasitol 1997; 27:1221.</a></li><li><a class="nounderline abstract_t">Maleewong W, Wongkham C, Intapan PM, Pipitgool V. Fasciola gigantica-specific antigens: purification by a continuous-elution method and its evaluation for the diagnosis of human fascioliasis. Am J Trop Med Hyg 1999; 61:648.</a></li><li><a class="nounderline abstract_t">Intapan PM, Maleewong W, Wongkham C, et al. Excretory-secretory antigenic components of adult Fasciola gigantica recognized by infected human sera. Southeast Asian J Trop Med Public Health 1998; 29:579.</a></li><li><a class="nounderline abstract_t">Sadaow L, Yamasaki H, Morishima Y, et al. Effectiveness of Fasciola gigantica excretory-secretory and recombinant cathepsin L antigens for rapid diagnosis of human fascioliasis using immunochromatographic devices. Parasitol Res 2020; 119:3691.</a></li><li><a class="nounderline abstract_t">Marcilla A, Bargues MD, Mas-Coma S. A PCR-RFLP assay for the distinction between Fasciola hepatica and Fasciola gigantica. Mol Cell Probes 2002; 16:327.</a></li></ol></div><div id="topicVersionRevision">Topic 5676 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153314" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of fascioliasis in human endemic areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153314" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology of fascioliasis in human endemic areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35709246" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Geospatial analysis of the associations between environmental contamination with livestock feces and children with chronic fascioliasis in the Anta province of Cusco, Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35162146" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : One Health Action against Human Fascioliasis in the Bolivian Altiplano: Food, Water, Housing, Behavioural Traditions, Social Aspects, and Livestock Management Linked to Disease Transmission and Infection Sources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23836562" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Domestically acquired fascioliasis in northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23998260" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatic lesions and eosinophilia in an urban dweller.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622408" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35278366" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology of Fasciola spp. in the intermediate host in China: A potential risk for fasciolosis transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2822181" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diseases caused by liver flukes and cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589147" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An outbreak of acute fascioliasis among Aymara Indians in the Bolivian Altiplano.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7837967" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fascioliasis in developed countries: a review of classic and aberrant forms of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113327" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33261674" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Towards the comprehension of fasciolosis (re-)emergence: an integrative overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254167" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258225" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Asymptomatic fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30628571" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Case Report: Hepatic Fascioliasis in a Young Afghani Woman with Severe Wheezing, High-Grade Peripheral Eosinophilia, and Liver Lesions: A Brief Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374966" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hiding in the Water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725803" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20872336" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fasciola hepatica-induced acute pancreatitis: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22171131" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical presentation and management of Fasciola hepatica infection: single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15891121" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cutaneous fascioliasis: a case report in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16099006" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fasciola hepatica in the human eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31507248" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Highlights of human ectopic fascioliasis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31933459" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Case Report: Subarachnoid Hemorrhage and Eosinophilic Meningitis due to Disseminated Fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1822928" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Liver fluke disease (fascioliasis): epidemiology, economic impact and public health significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23022355" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Halzoun, an allergic pharyngitis syndrome in Lebanon: the trematode Dicrocoelium dendriticum as an additional cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9231637" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Human fascioliasis: clinical features and diagnostic difficulties in Egyptian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1588869" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Human ectopic fascioliasis in Australia: first case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218685" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fascioliasis: case reports and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/158874" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fasciola hepatica human infection. Histopathological study of sixteen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812418" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Biliary fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19513838" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endoscopic management of biliary parasitic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9914695" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A monoclonal antibody diagnoses active Fasciola infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611560" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32974849" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Recent Developments in Recombinant Proteins for Diagnosis of Human Fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488926" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069474" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069474" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27549636" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Development of Two FhSAP2 Recombinant-Based Assays for Immunodiagnosis of Human Chronic Fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3138397" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antibody profiles by EITB and ELISA of cattle and sheep infected with Fasciola hepatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2760767" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dot-enzyme-linked immunosorbent assay (dot-ELISA) for the rapid diagnosis of human fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12557949" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evaluation of circulating Fasciola antigens in specific diagnosis of fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583902" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Detection of circulating E/S antigens in the sera of patients with fascioliasis by IELISA: a tool of serodiagnosis and assessment of cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257975" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of circulating antigens in blood to evaluate treatment of fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33278757" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fascioliasis and fasciolopsiasis: Current knowledge and future trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28915255" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Scrambled eggs: A highly sensitive molecular diagnostic workflow for Fasciola species specific detection from faecal samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821691" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Recombinase Polymerase Amplification Compared to Real-Time Polymerase Chain Reaction Test for the Detection of Fasciola hepatica in Human Stool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33113104" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of the PCR in a Combined Methodological Approach for the Study of Human Fascioliasis in an Endemic Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31701866" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Case Report: First Molecular Diagnosis of Liver Abscesses Due to Fasciola hepatica Acute Infection Imported from Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30056979" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Development of a multiplex quantitative PCR assay for detection and quantification of DNA from Fasciola hepatica and the intermediate snail host, Austropeplea tomentosa, in water samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12541122" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Human fascioliasis: MR imaging findings of hepatic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19908182" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hepatobiliary fascioliasis: imaging characteristics with a new finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34162437" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Imaging findings of human hepatic fascioliasis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425366" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sonographic findings of hepatobiliary fascioliasis accompanied by extrahepatic expansion and ectopic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2406786" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatobiliary fascioliasis: noninvasive imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128078" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781945" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15264986" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chemotherapy for major food-borne trematodes: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15264986" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chemotherapy for major food-borne trematodes: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256419" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34152949" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31638149" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Triclabendazole in the treatment of human fascioliasis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401189" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Human fascioliasis in Egyptian children: successful treatment with triclabendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389487" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Imported Fasciola hepatica infection in the United States and treatment with triclabendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22880138" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909440" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11421375" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15566392" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733042" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366485" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Triclabendazole progress report, 2005-2009: an advancement of learning?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762782" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33267701" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22607719" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27049013" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Current Threat of Triclabendazole Resistance in Fasciola hepatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808543" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32193176" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment failure after multiple courses of triclabendazole in a Portuguese patient with fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33862276" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31505596" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Crawling Into View.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25473389" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Finding of biliary fascioliasis by endoscopic ultrasonography in a patient with eosinophilic liver abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22744320" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : New developments in epidemiology, diagnosis, and treatment of fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692168" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful treatment of human fascioliasis with nitazoxanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12534412" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337331" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588772" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939646" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Fasciola hepatica Infection Risk for Adult Household Members Living with Children with Fascioliasis in Cusco, Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394193" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Immunological approaches for the control of fasciolosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10548303" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fasciola gigantica-specific antigens: purification by a continuous-elution method and its evaluation for the diagnosis of human fascioliasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10437961" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Excretory-secretory antigenic components of adult Fasciola gigantica recognized by infected human sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33009945" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effectiveness of Fasciola gigantica excretory-secretory and recombinant cathepsin L antigens for rapid diagnosis of human fascioliasis using immunochromatographic devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477436" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A PCR-RFLP assay for the distinction between Fasciola hepatica and Fasciola gigantica.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
